News

Ophthalmology Times16h
NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
ANI Pharma drops as clinical trial for eye implant fails against Regeneron’s Eylea
ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...
ANI Pharma Trial of Iluvien Misses Primary Endpoint
In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...
Healio1d
Eylea HD extends dosing intervals in DME, wet AMD
In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...
Clinical Trials Arena on MSN1d
ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial
The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...
TipRanks on MSN2d
ANI Pharmaceuticals reports results from clinical trial of Iluvien
ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...